Source: CureToday articles
Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.
Recent Content
- Alternating Glivec and Stivarga Doesn’t Improve Advanced GIST Outcomes
- A Dose of Inspiration: Celebrating the Pharmacist-Patient Relationship During Patient Experience Week
- Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
- Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer
- AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
- How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer
- AACR 2025: ctDNA Testing Identifies Recurrence Risk Within Weeks of Surgery in Colorectal Cancer
- AACR 2025: ctDNA-Guided Adjuvant PD-1 Blockade Shows Promise for Patients With Resected dMMR Solid Tumors
- TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
- Fellowship Focus: Elevating Pediatric Medication Safety Through Data, AI, and Collaboration